Molecular genetics analysis of hereditary breast and ovarian cancer patients in India

<p>Abstract</p> <p>Background</p> <p>Hereditary cancers account for 5–10% of cancers. In this study <it>BRCA1</it>, <it>BRCA2 </it>and <it>CHEK2</it>*(1100delC) were analyzed for mutations in 91 HBOC/HBC/HOC families and early onset b...

Full description

Bibliographic Details
Main Authors: Soumittra Nagasamy, Meenakumari Balaiah, Parija Tithi, Sridevi Veluswami, Nancy Karunakaran N, Swaminathan Rajaraman, Rajalekshmy Kamalalayam R, Majhi Urmila, Rajkumar Thangarajan
Format: Article
Language:English
Published: BMC 2009-08-01
Series:Hereditary Cancer in Clinical Practice
Online Access:http://www.hccpjournal.com/content/7/1/13
id doaj-15c5aeb7b5a34b3696c920e9be875bc8
record_format Article
spelling doaj-15c5aeb7b5a34b3696c920e9be875bc82020-11-24T23:08:23ZengBMCHereditary Cancer in Clinical Practice1897-42872009-08-01711310.1186/1897-4287-7-13Molecular genetics analysis of hereditary breast and ovarian cancer patients in IndiaSoumittra NagasamyMeenakumari BalaiahParija TithiSridevi VeluswamiNancy Karunakaran NSwaminathan RajaramanRajalekshmy Kamalalayam RMajhi UrmilaRajkumar Thangarajan<p>Abstract</p> <p>Background</p> <p>Hereditary cancers account for 5–10% of cancers. In this study <it>BRCA1</it>, <it>BRCA2 </it>and <it>CHEK2</it>*(1100delC) were analyzed for mutations in 91 HBOC/HBC/HOC families and early onset breast and early onset ovarian cancer cases.</p> <p>Methods</p> <p>PCR-DHPLC was used for mutation screening followed by DNA sequencing for identification and confirmation of mutations. Kaplan-Meier survival probabilities were computed for five-year survival data on Breast and Ovarian cancer cases separately, and differences were tested using the Log-rank test.</p> <p>Results</p> <p>Fifteen (16%) pathogenic mutations (12 in <it>BRCA1 </it>and 3 in <it>BRCA2</it>), of which six were novel <it>BRCA1 </it>mutations were identified. None of the cases showed <it>CHEK2</it>*1100delC mutation. Many reported polymorphisms in the exonic and intronic regions of <it>BRCA1 </it>and <it>BRCA2 </it>were also seen. The mutation status and the polymorphisms were analyzed for association with the clinico-pathological features like age, stage, grade, histology, disease status, survival (overall and disease free) and with prognostic molecular markers (ER, PR, c-erbB2 and p53).</p> <p>Conclusion</p> <p>The stage of the disease at diagnosis was the only statistically significant (p < 0.0035) prognostic parameter. The mutation frequency and the polymorphisms were similar to reports on other ethnic populations. The lack of association between the clinico-pathological variables, mutation status and the disease status is likely to be due to the small numbers.</p> http://www.hccpjournal.com/content/7/1/13
collection DOAJ
language English
format Article
sources DOAJ
author Soumittra Nagasamy
Meenakumari Balaiah
Parija Tithi
Sridevi Veluswami
Nancy Karunakaran N
Swaminathan Rajaraman
Rajalekshmy Kamalalayam R
Majhi Urmila
Rajkumar Thangarajan
spellingShingle Soumittra Nagasamy
Meenakumari Balaiah
Parija Tithi
Sridevi Veluswami
Nancy Karunakaran N
Swaminathan Rajaraman
Rajalekshmy Kamalalayam R
Majhi Urmila
Rajkumar Thangarajan
Molecular genetics analysis of hereditary breast and ovarian cancer patients in India
Hereditary Cancer in Clinical Practice
author_facet Soumittra Nagasamy
Meenakumari Balaiah
Parija Tithi
Sridevi Veluswami
Nancy Karunakaran N
Swaminathan Rajaraman
Rajalekshmy Kamalalayam R
Majhi Urmila
Rajkumar Thangarajan
author_sort Soumittra Nagasamy
title Molecular genetics analysis of hereditary breast and ovarian cancer patients in India
title_short Molecular genetics analysis of hereditary breast and ovarian cancer patients in India
title_full Molecular genetics analysis of hereditary breast and ovarian cancer patients in India
title_fullStr Molecular genetics analysis of hereditary breast and ovarian cancer patients in India
title_full_unstemmed Molecular genetics analysis of hereditary breast and ovarian cancer patients in India
title_sort molecular genetics analysis of hereditary breast and ovarian cancer patients in india
publisher BMC
series Hereditary Cancer in Clinical Practice
issn 1897-4287
publishDate 2009-08-01
description <p>Abstract</p> <p>Background</p> <p>Hereditary cancers account for 5–10% of cancers. In this study <it>BRCA1</it>, <it>BRCA2 </it>and <it>CHEK2</it>*(1100delC) were analyzed for mutations in 91 HBOC/HBC/HOC families and early onset breast and early onset ovarian cancer cases.</p> <p>Methods</p> <p>PCR-DHPLC was used for mutation screening followed by DNA sequencing for identification and confirmation of mutations. Kaplan-Meier survival probabilities were computed for five-year survival data on Breast and Ovarian cancer cases separately, and differences were tested using the Log-rank test.</p> <p>Results</p> <p>Fifteen (16%) pathogenic mutations (12 in <it>BRCA1 </it>and 3 in <it>BRCA2</it>), of which six were novel <it>BRCA1 </it>mutations were identified. None of the cases showed <it>CHEK2</it>*1100delC mutation. Many reported polymorphisms in the exonic and intronic regions of <it>BRCA1 </it>and <it>BRCA2 </it>were also seen. The mutation status and the polymorphisms were analyzed for association with the clinico-pathological features like age, stage, grade, histology, disease status, survival (overall and disease free) and with prognostic molecular markers (ER, PR, c-erbB2 and p53).</p> <p>Conclusion</p> <p>The stage of the disease at diagnosis was the only statistically significant (p < 0.0035) prognostic parameter. The mutation frequency and the polymorphisms were similar to reports on other ethnic populations. The lack of association between the clinico-pathological variables, mutation status and the disease status is likely to be due to the small numbers.</p>
url http://www.hccpjournal.com/content/7/1/13
work_keys_str_mv AT soumittranagasamy moleculargeneticsanalysisofhereditarybreastandovariancancerpatientsinindia
AT meenakumaribalaiah moleculargeneticsanalysisofhereditarybreastandovariancancerpatientsinindia
AT parijatithi moleculargeneticsanalysisofhereditarybreastandovariancancerpatientsinindia
AT srideviveluswami moleculargeneticsanalysisofhereditarybreastandovariancancerpatientsinindia
AT nancykarunakarann moleculargeneticsanalysisofhereditarybreastandovariancancerpatientsinindia
AT swaminathanrajaraman moleculargeneticsanalysisofhereditarybreastandovariancancerpatientsinindia
AT rajalekshmykamalalayamr moleculargeneticsanalysisofhereditarybreastandovariancancerpatientsinindia
AT majhiurmila moleculargeneticsanalysisofhereditarybreastandovariancancerpatientsinindia
AT rajkumarthangarajan moleculargeneticsanalysisofhereditarybreastandovariancancerpatientsinindia
_version_ 1725614481523867648